



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO.
	11617-004-999	10/538,695
	APPLICANT:	Park et al.
	FILING DATE:	ART UNIT: CONF. NO.: June 10, 2005 2817 1615 6982

### U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS*	DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Ha	A01 5,451,409	09/19/1995	Rencher et al.	
↑	A02 5,591,452	01/07/1997	Miller et al.	
	A03 5,807,583	09/15/1998	Kristensen et al.	
	A04 5,849,240	12/15/1998	Miller et al.	
	A05 5,891,471	04/06/1999	Miller et al.	
	A06 5,955,104	09/21/1999	Momberger et al.	
	A07 5,965,163	10/12/1999	Miller et al.	
	A08 5,968,551	10/19/1999	Oshlack et al.	
	A09 6,103,261	08/15/2000	Chasin et al.	
	A10 6,143,322	11/07/2000	Sackler et al.	
	A11 6,159,501	12/12/2000	Skinhoj	
	A12 6,162,467	12/19/2000	Miller et al.	
	A13 6,254,887	07/03/2001	Miller et al.	
	A14 6,261,599	07/17/2001	Oshlack et al.	
	A15 6,290,990	09/18/2001	Grabowski et al.	
↓	A16 6,294,195	09/25/2001	Oshlack et al.	
Ha	A17 6,306,438	10/23/2001	Oshlack et al.	
Ha	A18 6,335,033	01/01/2002	Oshlack et al.	

### FOREIGN PATENT DOCUMENTS


EXAMINER'S INITIALS*	Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
					YES	NO
Ha	B01 WO 93/15753	08/19/1993	Kaken Pharmaceutical Co. Ltd.			X
↑	B02 WO 95/14460	06/01/1995	Euroceltique S.A.			
	B03 WO 98/04249	02/05/1998	Asta Medica Aktiengesellschaft			
	B04 WO 99/47128	09/23/1999	Bristol-Myers Squibb Company			
↓	B05 WO 04/080447	09/23/2004	Euroceltique, S.A.			
Ha	B06 EP I 125 586	08/22/2001	Tanabe Seiyaku Co., Ltd.			

EXAMINER <u>HASAN S. AHMED</u>	DATE CONSIDERED <u>22 JANUARY 2007</u>
--------------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 149/PTO

MAR 20 2005


**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**  
 (Use several sheets if necessary)

**ATTY DOCKET NO.** 11617-004-999      **APPLICATION NO.** 10/538,695
**APPLICANT:**

Park et al.

**FILING DATE:**

June 10, 2005

**ART UNIT: CONF. NO.:**

2817 615 6982

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS*		Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
						YES	NO

**NON PATENT LITERATURE DOCUMENTS** (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s)s, volume, publisher, city and/or country where published., etc.)

EXAMINER'S INITIALS*		
Hasan	COI	AIMAN et al., "Controlled release of tramadol hydrochloride from matrices prepared using glyceryl behenate," <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2001, 52: 231-235

EXAMINER *Hasan S. Ahmed*DATE CONSIDERED *22 JANUARY 2007*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.